Literature DB >> 25434696

How do we understand the disagreement in the frequency of surgical site infection between the CDC and Clavien-Dindo classifications?

Takanobu Yamamoto1, Satoshi Takahashi2, Koji Ichihara3, Yoshiki Hiyama3, Teruhisa Uehara3, Jiro Hashimoto3, Megumi Hirobe3, Naoya Masumori3.   

Abstract

To clarify the discrepancy in the incidence and severity of surgical site infections (SSI) for radical cystectomy between reports based on the CDC guideline and those using the Clavien-Dindo classification we evaluated 449 consecutive patients who underwent radical cystectomy for bladder cancer between 1990 and 2012. Of the 115 (25.6%) patients with SSI defined by the CDC guideline, 89 could be analyzed. We compared the SSI rates and severity defined by the CDC guideline and Clavien-Dindo classifications. There were 58 patients with superficial SSI, 16 with deep SSI, and 15 with organ/space SSI according to the CDC guideline. All patients with organ/space SSI were judged as "not having SSI" by the Clavien-Dindo classification. They were classified as having "intestinal prolapse", "intestinal fistula", "abdominal abscess" and "pelvic abscess." There was a significant association between the treatment duration and depth of SSI based on the CDC guideline by Spearman's rank-correlation coefficient (p < 0.001, r = 0.614) and with the grade of complications (p < 0.001, r = 0.632) in the Clavien-Dindo classification. Multivariate analysis showed that patients with grade III SSI in the Clavien-Dindo classification needed a significantly longer treatment duration. It is necessary to be aware that a discrepancy can occur automatically due to the different natures of the definitions. Using the CDC guideline, we can effectively estimate the future treatment period when SSI occurs. With the Clavien-Dindo classification, grade III SSI requires a longer treatment duration.
Copyright © 2014 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bladder cancer; CDC guideline; Clavien-Dindo classification; Cystectomy; Surgical site infection

Mesh:

Year:  2014        PMID: 25434696     DOI: 10.1016/j.jiac.2014.10.016

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  5 in total

1.  Predictors of surgical site infection after radical cystectomy: should we enhance surgical antibiotic prophylaxis?

Authors:  Hanan Goldberg; Chen Shenhar; Hadar Tamir; Roy Mano; Jack Baniel; David Margel; Daniel Kedar; David Lifshitz; Ofer Yossepowitch
Journal:  World J Urol       Date:  2018-09-15       Impact factor: 4.226

2.  A call for standardization of wound events reporting following ventral hernia repair.

Authors:  I N Haskins; C M Horne; D M Krpata; A S Prabhu; L Tastaldi; Arielle J Perez; S Rosenblatt; B K Poulose; M J Rosen
Journal:  Hernia       Date:  2018-02-10       Impact factor: 4.739

3.  Retrospective observational cohort study on cosmetic outcome of using Ti-Ni memory alloy wire for intradermal suture following mastectomy in patients with breast cancer.

Authors:  Gang Li; Sida Qin; Xin Sun; Jiansheng Wang; Yunfeng Zhang; Jia Zhang; Jing Zhang; Shou-Ching Tang; Hong Ren
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

4.  Technological Advances in Clinical Definition and Surveillance Methodology for Surgical Site Infection Incorporating Surgical Site Imaging and Patient-Generated Health Data.

Authors:  Robert G Sawyer; Heather L Evans; Traci L Hedrick
Journal:  Surg Infect (Larchmt)       Date:  2019-08-28       Impact factor: 2.150

Review 5.  Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature.

Authors:  Christian Guido Ruf; Simon Krampe; Cord Matthies; Petra Anheuser; Tim Nestler; Jörg Simon; Hendrik Isbarn; Klaus Peter Dieckmann
Journal:  World J Surg Oncol       Date:  2020-09-24       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.